BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $31.38 Average PT from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a consensus rating of “Hold” from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $31.3750.

Several research analysts have recently commented on BLFS shares. Stephens restated an “equal weight” rating and set a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a research note on Monday, July 27th. Maxim Group cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Craig Hallum downgraded BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research note on Wednesday, July 22nd. Jefferies Financial Group lowered BioLife Solutions from a “buy” rating to a “hold” rating and boosted their target price for the stock from $30.00 to $31.00 in a report on Thursday, July 23rd. Finally, HC Wainwright downgraded shares of BioLife Solutions from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $32.00 to $31.00 in a report on Thursday, July 23rd.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently made changes to their positions in the business. Hantz Financial Services Inc. raised its position in BioLife Solutions by 42.4% in the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 796 shares in the last quarter. State of Wyoming acquired a new position in shares of BioLife Solutions in the 1st quarter worth approximately $52,000. WINTON GROUP Ltd bought a new position in shares of BioLife Solutions during the 2nd quarter worth approximately $201,000. AXQ Capital LP bought a new position in shares of BioLife Solutions during the 2nd quarter worth approximately $203,000. Finally, GAMMA Investing LLC boosted its stake in BioLife Solutions by 36.6% in the 2nd quarter. GAMMA Investing LLC now owns 8,996 shares of the medical equipment provider’s stock valued at $254,000 after buying an additional 2,410 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $35.43 on Thursday. The stock has a market cap of $1.73 billion, a PE ratio of 30.54 and a beta of 1.91. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $38.10. The stock’s 50-day moving average is $33.22 and its two-hundred day moving average is $26.39.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.88. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. The firm had revenue of $28.47 million for the quarter, compared to analyst estimates of $27.80 million. On average, equities research analysts anticipate that BioLife Solutions will post 0.03 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops and supplies tools and services used in the development, manufacture, preservation and distribution of cell and gene therapies. Its products are designed to help maintain the viability and functionality of cells, tissues and other biological materials during processing, freezing, storage and transportation.

The company’s portfolio includes cell and tissue preservation media, thawing and processing solutions, cryogenic storage systems, controlled-rate freezing equipment and related bioproduction technologies.